Nervonik, a medical device startup focusing on neurotechnology approaches to peripheral nerve stimulation, has received approval to conduct a first-in-human feasibility study utilizing its proprietary technology. The focus will be on chronic pain of peripheral nerve origin, although the novel technology will eventually be utilized for a variety of medical indications.
Enrollment in the study is anticipated to begin later in the 3rd quarter of 2024 with presentation of results following.
